so heavily with posts being bumped down to the extent that this OPK board is?
I can understand why shorts are so desperate, but give me a break. These message boards do not influence the price of a stock, not long term anyway if any at all, and even if they did, it should be obvious to the ones bumping posts that it's not working in their favor!
Have you noticed on the OPKO homepage under "Diagnostics" they already have the page and platform announcing OURLABS being the entity to commercialize 4Kscore?
I can tell you that the people at OURLABS in Nashville, TN, which is not too far from where I live, are being very tight lipped as to the anticipated launch date of 4Kscore. They will not disclose any information other than recently, it was advised that it was coming "very soon."
Shorts are toast.
Bjoel5150, $50 party in Hawaii sounds most excellent! I just hope we get to vegas sometime soon next year!
to talk about what he was working on in Russia?
Pharmsynthez Announces Product Pipeline Progress 31 July 2013
Pharmsynthez Announces Product Pipeline Progress
Recruitment surpasses half-way point for MyeloXEN® Phase IIa and
Rayaldy™ Phase III Studies
St. Petersburg, Russia - Pharmsynthez the leading Russian biopharmaceutical company that specializes in the development, manufacture and distribution of pharmaceuticals announces today that key pipeline products MyeloXEN® and Rayaldy™ have surpassed the half-way point for enrollment in their respective ongoing clinical trials.
Rayaldy™ (CTAP101 Capsules) is a first-in-class vitamin D prohormone treatment with modified release being developed by OPKO Health, Inc. for secondary hyperthyroidism (SHPT) in stage 3 and 4 chronic kidney disease (CKD) patients with vitamin D insufficiency. The first of two identical Phase III randomized, double-blind, placebo controlled, multi-site studies carried out by OPKO Health has enrolled over half of the 210 patients set to enter the study. The endpoints of both studies, which will be conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).
Pharmsynthez has exclusive manufacturing and distribution rights to Rayaldy™ in Russia and the CIS. Results from the Phase III trials are expected in in the third quarter of 2014.
Dmitry Genkin, Chairman of Pharmsynthez, commented, “We are excited to report on the successful recruitment progress of MyeloXEN® and Rayaldy™. Both products have significant commercial potential if approved and we very much look forward to reporting the results from these studies by the end of the year for MyeloXEN® and in the third quarter of 2014 for Rayaldy™.”
As I made very clear, Frost's purchases are:
- negligible relative to daily volume (they are not proppoing up the price by themselves)
- negligible relative to the size of his position (ie. he is not increasing his position size by a material amount)
- negligible relative to the number of shares outstanding.
These continue to be the case. The authors who say that frost is "pushing up the price" are demonstrably wrong. What frost is doing is maintaining his position size in the face of all of the dilution coming via acquisitions.
Cramer has always had a buy on Opko and he personally loves Frost.
That said, I am no longer short. Nothing will take this stock down, and sooner or later they may start producing some real revenues.
good luck on your position.
thanks for writing.
It's no where near making up for your $5, $6, $7, $8, and $9 short positions is it?
That's incredible that there are over 34 million short shares so underwater!
For real! If I wasn't at work all this weekend on my second job I'd be out chasing some skits not sitting on a message board! When I post I am always at work on one of two jobs. They really must be mentally challenged. Or, it really is shorts that are so underwater they are going to lose it all on their OPK short positions.
They are like poker players who refuse to accept the fact that although they may have a good hand, the one who keeps raising the bet hasd a better hand. They will, out of EGO, sit there and throw in their entire bankroll only to lose it all!
CL we knew that because he shorted OPK probably way under $6, and the LOSER spends his time robo-posting, like it's really going to make a difference in the PPS anyway, lol. if it was OPK would be way down over the last couple of months.
At least when I am posting I'm at work passing time while I am getting paid to be at work. These goons spend all weekend posting probably for about .03 a bump.
Or does it even matter? Does OPK there necessarily always have to follow it in the US? It seems it would always be close anyway?
Thanks Cl, so it was down compared to Friday's close here, or are they a day behind? Do you think OPK on the TASE pretty much follows what the US OPK does if the TASE is a day behind, or are they a day ahead?
"Opko Health: Highly Questionable Management Transactions And Valuation"
Disclosure: I have no positions in any stocks mentioned, but may initiate a short position in OPK over the next 72 hours.
Sure hope he didn't initiate that short position!
Yea and the "CEO" name is "Yang Yu"
Frost is going to HANG Yang yu!
Still don't think it goes on?
Congress Quickly And Quietly Rolls Back Insider Trading Rules For Itself
from the can't-mess-with-the-profits dept
In November of 2011, the TV show 60 Minutes did a big expose on insider trading within Congress. While everyone else is subject to basic insider trading rules, it turned out that members of Congress were exempt from the rules. And, as you would imagine, many in Congress have access to market-moving, non-public information. And they made use of it. To make lots and lots of money. Of course, after that report came out and got lots of attention, Congress had to act, and within months they had passed the STOCK Act with overwhelming support in Congress to make insider trading laws that apply to everyone else finally apply to Congress and Congressional staffers as well. As that link notes:
The lopsided votes showed lawmakers desperate to regain public trust in an election year, when the public approval rating of Congress has sunk below 15 percent.
Of course, here we are in 2013 and, lo and behold, it is no longer an election year. And apparently some of the details of the ban on insider trading were beginning to chafe Congressional staffers, who found it hard to pad their income with some friendly trades on insider knowledge.
So... with very little fanfare, Congress quietly rolled back a big part of the law late last week. Specifically the part that required staffers to post disclosures about their financial transactions, so that the public could make sure there was no insider trading going on. Congress tried to cover up this fairly significant change because they, themselves, claimed that it would pose a "national risk" to have this information public. A national risk to their bank accounts.
It was such a national risk that Congress did the whole thing quietly, with no debate. The bill was introduced in the Senate on Thursday and quickly voted on late that night when no one was paying attention. Friday afternoon (the best time to sneak through news), the House picked it up by unanimous consent. The House ignored its own promise to give Congress three days to read a bill before holding a vote, because this kind of thing is too important to let anyone read the bill before Congress had to pass it.
And, of course, yesterday, President Obama signed it into law. Because the best way to rebuild trust in Congress, apparently, is to roll back the fact that people there need to obey the same laws as everyone else. That won't lead the public to think that Congress is corrupt. No, not at all.
The measure scaled back online disclosures for the executive branch from 28,000 employees to 67. Ironically, because of the conflict-of-interest rules applicable to senior executive branch officials, these 67 officials cannot even trade stocks in their field. Executive officials who could pose a problem of insider trading, such as deputy directors and other senior management, are now exempt from online disclosure.
Also exempted from online disclosure are all congressional staffers. This is particularly troublesome because there is no comparable conflict-of-interest rule to prevent congressional staff from playing in the stock market. Granted, staffers still must disclose stock trades on paper filings with congressional offices, but these are available only to those who can make the trip to Capitol Hill, and only in PDF format, requiring a researcher to peruse through each of the thousands of filings individually. There is no ability to search for stock trades reported in the past 30 days, or to identify just staffers that engage in stock trading.
So now only members of Congress, congressional candidates and 67 executive branch officials need disclose their personal finances online. But even these records have been made difficult to review.
At Congress’ request, the National Academy of Public Administration reviewed the online disclosure of the STOCK Act. The study, which largely excluded the views of transparency groups, offered conflicting recommendations ranging from delaying implementation of the online disclosure provision to questioning the value of searchable, sortable and downloadable transparency databases altogether.